# Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)

> **NCT00504400** · PHASE2 · COMPLETED · sponsor: **University Hospital, Bonn** · enrollment: 10 (actual)

## Conditions studied

- Type 2 Idiopathic Macular Telangiectasia

## Interventions

- **DRUG:** Intravitreal injection ranibizumab

## Key facts

- **NCT ID:** NCT00504400
- **Lead sponsor:** University Hospital, Bonn
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2009-06
- **Final completion:** 2009-09
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2009-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00504400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00504400, "Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT00504400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*